Equillium (Nasdaq:EQ) - Stock Price, News & Analysis

EQ Stock Overview

A clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need.

About the company

EQ fundamental analysis
Snowflake Score
Valuation	3/6
Future Growth	0/6
Past Performance	0/6
Financial Health	5/6
Dividends	0/6

Rewards

Earnings have grown 2.4% per year over the past 5 years

Trading at good value compared to peers and industry

Risk Analysis

Has less than 1 year of cash runway

Earnings are forecast to decline by an average of 37.4% per year for the next 3 years

Currently unprofitable and not forecast to become profitable over the next 3 years

Does not have a meaningful market cap ($30M)

+ 2 more risks

Equillium, Inc. Competitors

Palatin Technologies

NYSEAM:PTN

US$24.8m

BioXcel Therapeutics

NasdaqCM:BTAI

US$23.5m

Nuo Therapeutics

OTCPK:AURX

US$25.0m

Bolt Biotherapeutics

NasdaqGS:BOLT

US$23.6m

Price History & Performance

Summary of all time highs, changes and price drops for Equillium
Historical stock prices
Current Share Price	US$0.80
52 Week High	US$3.25
52 Week Low	US$0.45
Beta	1.84
11 Month Change	-26.69%
3 Month Change	16.83%
1 Year Change	6.51%
33 Year Change	-88.18%
5 Year Change	-78.98%
Change since IPO	-94.29%

Recent updates

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Aug 12

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

May 03

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Mar 26

Equillium GAAP EPS of -$0.41 in-line

Aug 15

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Oct 08

Is Equillium, Inc.'s (NASDAQ:EQ) Shareholder Ownership Skewed Towards Insiders?

Mar 09

Equillium prices $30M registered direct offering

Feb 04

Equillium (EQ) Investor Presentation - Slideshow

Dec 04

How Much Of Equillium, Inc. (NASDAQ:EQ) Do Insiders Own?

Nov 24

FDA gives green signal to Equillium's late-stage COVID-19 trial

Oct 30

Shareholder Returns

	EQ	US Biotechs	US Market
7D	-7.1%	-1.3%	1.2%
1Y	6.5%	23.2%	30.2%

Return vs Industry: EQ underperformed the US Biotechs industry which returned 23.2% over the past year.

Return vs Market: EQ underperformed the US Market which returned 30.2% over the past year.

Price Volatility

Is EQ's price volatile compared to industry and market?
EQ volatility
EQ Average Weekly Movement	11.5%
Biotechs Industry Average Movement	10.2%
Market Average Movement	6.4%
10% most volatile stocks in US Market	15.1%
10% least volatile stocks in US Market	3.1%

Stable Share Price: EQ's share price has been volatile over the past 3 months.

Volatility Over Time: EQ's weekly volatility has decreased from 17% to 11% over the past year, but is still higher than 75% of US stocks.

About the Company

Founded	Employees	CEO	Website
2017	45	Bruce Steel	www.equilliumbio.com

Equillium, Inc., a clinical-stage biotechnology company, develops and sells products to treat severe autoimmune and inflammatory, or immuno-inflammatory disorders with unmet medical need. The company’s lead product candidate is itolizumab (EQ001), a first-in-class monoclonal antibody that targets the immune checkpoint receptor CD6, which is in Phase III clinical trials for the treatment of acute graft-versus-host disease; completed Phase I clinical trial for the treatment of ulcerative colitis; and Phase I clinical trial for the treatment of lupus nephritis. It also develops EQ101 completed phase 1/2 for treatment of cutaneous T cell lymphoma and alopecia areata; and EQ302 to treat gastrointestinal indications.

Equillium, Inc. Fundamentals Summary

How do Equillium's earnings and revenue compare to its market cap?
EQ fundamental statistics
Market cap	US$30.11m
Earnings (TTM)	-US$8.32m
Revenue (TTM)	US$42.62m

0.7x

P/S Ratio

-3.4x

P/E Ratio

Is EQ overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EQ income statement (TTM)
Revenue	US$42.62m
Cost of Revenue	US$0
Gross Profit	US$42.62m
Other Expenses	US$50.94m
Earnings	-US$8.32m

Last Reported Earnings

Jun 30, 2024

Next Earnings Date

n/a

Earnings per share (EPS)	-0.23
Gross Margin	100.00%
Net Profit Margin	-19.52%
Debt/Equity Ratio	0%

How did EQ perform over the long term?

See historical performance and comparison

EQ Stock Overview

Rewards

Risk Analysis

Equillium, Inc. Competitors

NYSEAM:PTN

US$24.8m

NasdaqCM:BTAI

US$23.5m

OTCPK:AURX

US$25.0m

NasdaqGS:BOLT

US$23.6m

Price History & Performance

Recent News & Updates

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Financial position

New major risk - Share price stability

Recent updates

Consensus revenue estimates increase by 35%

Forecast to breakeven in 2024

New minor risk - Shareholder dilution

Second quarter 2024 earnings: EPS and revenues exceed analyst expectations

New major risk - Financial position

New major risk - Share price stability

Equillium, Inc. Announces Positive Interim Analysis from Phase 3 Equator Study of Itolizumab in Acute Graft-Versus-Host Disease

Equillium Receives Non-Compliance Letter from Nasdaq Regarding Minimum Bid Price Requirement

Benign Growth For Equillium, Inc. (NASDAQ:EQ) Underpins Stock's 54% Plummet

Equillium, Inc. Announces Topline Data from Its Phase 2, Single Dose, Proof-Of-Concept Study of Eq101

Equillium, Inc. Announces Interim Enrollment Achieved in Phase 3 EQUATOR Study of Itolizumab in Acute Graft-Versus-Host Disease

New minor risk - Profitability

Forecast to breakeven in 2024

First quarter 2024 earnings released: US$0.078 loss per share (vs US$0.11 loss in 1Q 2023)

We Think Equillium (NASDAQ:EQ) Needs To Drive Business Growth Carefully

Price target increased by 9.5% to US$6.75

Equillium Announces Positive Topline Data from the Type B Portion of the Phase 1B Equalise Study of Itolizumab in Lupus Nephritis

Consensus EPS estimates fall by 188%

Little Excitement Around Equillium, Inc.'s (NASDAQ:EQ) Revenues

New major risk - Share price stability

Equillium Announces Update on Multi-Cytokine Inhibitors EQ101 & EQ102 in Development for Alopecia Areata and Celiac Disease

New minor risk - Share price stability

Price target decreased by 10% to US$6.17

Equillium, Inc. Presents Positive Data from Phase 1B EQUALISE Study At the 2023 Annual Meeting of the American College of Rheumatology

Equillium Announces Data from Phase 1b EQUALISE Study Presented at the 2023 Annual Meeting of the American Society of Nephrology

Equillium Gets an Additional 180-Day Grace Period to Regain Compliance with the Minimum Bid Price Requirement

Consensus revenue estimates increase by 23%

Analyst Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Earnings Release: Here's Why Analysts Cut Their Equillium, Inc. (NASDAQ:EQ) Price Target To US$6.06

Equillium, Inc. Promotes Maple Fung to the Position of Chief Medical Officer

Equillium, Inc. (NasdaqGM:EQ) announces an Equity Buyback for $7.5 million worth of its shares.

Consensus revenue estimates increase by 187%

Broker Revenue Forecasts For Equillium, Inc. (NASDAQ:EQ) Are Surging Higher

Consensus revenue estimates increase by 17%

Does Equillium (NASDAQ:EQ) Have A Healthy Balance Sheet?

Biocon Limited in Collaboration with Equillium, Inc. Initiate Phase 2 Clinical Study of Itolizumab in Patients with Ulcerative Colitis

Price target decreased to US$12.00

Insufficient new directors

Equillium, Inc. Announces Initiation of Phase 2 Study of Eq101 A First-In-Class Multi-Cytokine Inhibitor of Il-2, Il-9 and Il-15 Targeting Alopecia Areata

Equillium Announces Initiation of Phase 1 study of EQ102, A First-in-Class Multi-Cytokine Inhibitor of IL-15 and IL-21 Targeting Celiac Disease

Price target decreased to US$12.00

Price target increased to US$14.00

Equillium, Inc. Reports Interim Results from the Type B Portion of the EQUALIZE Study Evaluating Itolizumab

Equillium, Inc. (NasdaqGM:EQ) entered into a definitive merger agreement to acquire Metacrine, Inc. (NasdaqCM:MTCR).

Equillium GAAP EPS of -$0.41 in-line

Insufficient new directors

Price target increased to US$13.75

Equillium, Inc., Annual General Meeting, May 24, 2022

Equillium, Inc. Announces Initiation of the Phase 3 EQUATOR Study of Itolizumab in First-line Acute Graft-Versus-Host Disease

Equillium, Inc. Appoints Barbara Troupin to its Board of Directors and as Member of Nominating and Corporate Governance Committee

Price target decreased to US$12.50

Equillium, Inc. (NasdaqGM:EQ) completed the acquisition of Bioniz Therapeutics, Inc. from Kevin Green for $330 million.

Equillium Announces Data from Phase 1B Equip Study in Patients with Uncontrolled Asthma

Senior VP & COO notifies of intention to sell stock

Equillium CEO Bruce Steel - Drugs For Autoimmune, Inflammatory Disorders (Video)

Equillium Announces Update to EQUALISE Study of Itolizumab in Patients with Systemic Lupus Erythematosus and Lupus Nephritis

Equillium, Inc. Announces Plans to Initiate Phase 3 Pivotal Study of Itolizumab in First-line Treatment of Acute Graft-Versus-Host Disease Following End-of-Phase 1 Meeting with the FDA

Equillium, Inc.(NasdaqGM:EQ) dropped from Russell Microcap Value Index

Equillium Inc Announces Positive Topline Results from the EQUATE Study in First-line Treatment of Acute Graft-Versus-Host Disease